Drugs / 7α-methyl-19-nortestosterone
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00812630 | Dec 2008 → Mar 2014 | hypertensive disorder | Population Council | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 7α-methyl-19-nortestosterone | “7α-methyl-19-nortestosterone (MENT)” NCT00812630 ↗ |
| Known as | MENT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00812630 ↗ |
| Route | Other | “subjects will apply MENT or placebo gel transdermally for 12 weeks” NCT00812630 ↗ |